Wegovy 5 Year Results — Long-Term Weight Loss & Health Data

Wegovy 5 Year Results — Long-Term Weight Loss & Health Data

The longest published data on Wegovy (semaglutide 2.4mg) extends 208 weeks. Just under four years. But the trajectory tells you everything you need to know about five-year expectations. Patients who stayed on the medication maintained a mean body weight reduction of 10.2% from baseline at the 208-week mark in the STEP 5 extension trial. That's not the dramatic 15–17% seen in the first 68 weeks, but it's sustained metabolic benefit that dietary intervention alone rarely achieves beyond two years.

We've worked with hundreds of patients navigating long-term GLP-1 therapy. The question isn't whether the medication works at five years. The data shows it does. The real question is what happens when patients stop, what the cardiovascular benefits actually are, and whether the current dose escalation protocols hold up over extended timelines.

What are the wegovy 5 year results showing in clinical trials?

Wegovy 5 year results from extension trials demonstrate sustained weight loss averaging 10.2% at 208 weeks (approximately four years) among patients who remained on treatment, with additional cardiovascular benefits including a 20% reduction in major adverse cardiovascular events (MACE) observed in the SELECT trial. Patients who discontinue treatment typically regain two-thirds of lost weight within 52 weeks, indicating that semaglutide functions as long-term metabolic management rather than a short-term intervention.

The wegovy 5 year results discussion centres on durability, not novelty. Semaglutide 2.4mg isn't a new compound in 2026. It's been FDA-approved since 2021, meaning the longest real-world patient cohorts are approaching the five-year mark now. What the published data shows is a plateau effect: weight loss stabilises between weeks 60–68, then holds relatively steady with minor fluctuations as long as treatment continues. This article covers the specific weight retention data, cardiovascular outcomes, discontinuation rebound patterns, and what the extension trials reveal about dose fatigue and side effect persistence beyond the standard trial endpoints.

Long-Term Weight Retention — What the Extension Data Actually Shows

The STEP 5 trial. The longest published Wegovy study as of 2026. Tracked patients for 208 weeks (approximately four years). At week 68, participants had achieved a mean body weight reduction of 15.2% from baseline. By week 208, that figure had declined slightly to 10.2%, still on treatment. This isn't medication failure. It's the expected metabolic equilibrium point where energy expenditure adapts to lower body weight and the initial water weight and glycogen depletion phases are long past.

Patients who discontinued semaglutide in the STEP 1 extension trial regained approximately 66% of their lost weight within one year of stopping. This rebound isn't psychological. It's hormonal. GLP-1 receptor agonists suppress ghrelin (the hunger hormone) and amplify satiety signaling via GLP-1 and PYY elevation. Remove the medication, and those pathways return to baseline within 4–5 weeks as semaglutide's half-life clears the system. The body doesn't 'remember' the lower weight setpoint. It reverts to the hormonal state that existed before treatment.

One pattern our team has observed consistently: patients who transition off Wegovy without structured metabolic support. Meaning resistance training, protein intake above 1.6g/kg, and planned refeeding protocols. Regain weight faster than those who treat discontinuation as a 12-week weaning process rather than a hard stop.

Cardiovascular Outcomes — The SELECT Trial's Five-Year Implications

The SELECT trial, published in the New England Journal of Medicine in late 2023, represents the most significant wegovy 5 year results beyond weight loss. This study enrolled over 17,600 adults with established cardiovascular disease and a BMI ≥27 but without diabetes, tracking them for a median follow-up of 40 months. Patients on semaglutide 2.4mg experienced a 20% reduction in major adverse cardiovascular events (MACE). A composite endpoint including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. Compared to placebo.

This wasn't a weight loss trial. It was a cardiovascular outcomes trial. The 20% MACE reduction occurred even in patients who lost less than 5% of their body weight, suggesting direct cardioprotective mechanisms beyond fat reduction alone. Proposed mechanisms include reduced systemic inflammation (measured via hsCRP reduction), improved endothelial function, and direct GLP-1 receptor activation in cardiac tissue that may reduce arrhythmia burden and myocardial oxygen demand.

What this means for five-year projections: if the MACE benefit holds at 40 months, it's reasonable to extrapolate similar or slightly enhanced benefit at 60 months, provided patients remain on therapy and don't experience dose fatigue or discontinuation due to side effects. Cardiovascular benefit isn't front-loaded. It accumulates over time as inflammatory markers decline and lipid profiles stabilise.

Wegovy 5 Year Results vs Alternatives — Patient Retention and Efficacy

The comparison underscores a critical point: wegovy 5 year results are strong relative to historical pharmaceutical interventions and far superior to lifestyle modification alone, but they aren't the ceiling. Tirzepatide's dual GIP and GLP-1 receptor agonism consistently produces 20–25% greater weight loss in head-to-head trials, and early cardiovascular data suggests similar or enhanced MACE reduction. Patients starting therapy in 2026 increasingly initiate on tirzepatide rather than semaglutide when insurance coverage allows, though Wegovy remains the gold standard for patients with established cardiovascular disease due to SELECT trial data.

Key Takeaways

• Wegovy maintains a mean 10.2% body weight reduction at 208 weeks (approximately four years) among patients who remain on treatment, according to STEP 5 extension data.
• Patients who discontinue semaglutide regain approximately two-thirds of lost weight within 52 weeks, reflecting the return of baseline ghrelin and satiety hormone levels as the medication clears.
• The SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major adverse cardiovascular events at 40 months, independent of the degree of weight loss achieved.
• Side effects. Primarily nausea, vomiting, and diarrhea. Peak during dose escalation but typically resolve by weeks 12–16; persistent GI intolerance affects approximately 7% of patients in clinical trials and 15–18% in real-world settings.
• Long-term efficacy requires continuous treatment; semaglutide does not reset metabolic setpoints or confer lasting hormonal changes after discontinuation.
• Tirzepatide (a dual GIP/GLP-1 agonist) shows superior weight loss outcomes in head-to-head comparisons, though Wegovy remains the best-studied option for cardiovascular risk reduction as of 2026.

What If: Wegovy Long-Term Scenarios

What If I've Been on Wegovy for Three Years and Weight Loss Has Plateaued?

If your weight has stabilised and you're no longer seeing monthly reduction despite adherence to the 2.4mg weekly dose, you've likely reached metabolic equilibrium. Consider three factors before escalating intervention: (1) body composition. Are you losing fat but maintaining or gaining lean mass through resistance training? Scale weight stagnation with improving body composition is a success, not a plateau. (2) Caloric drift. Most patients unconsciously increase intake by 200–400 calories/day as appetite suppression becomes familiar. Track intake for two weeks to identify drift. (3) Dose fatigue. Some patients experience reduced GLP-1 receptor sensitivity after 24+ months. Switching to tirzepatide (a dual agonist) may restore weight loss momentum if semaglutide efficacy has genuinely declined.

What If I Want to Stop Wegovy After Reaching Goal Weight?

Plan a structured discontinuation rather than an abrupt stop. The STEP 1 extension data shows that patients who stopped cold turkey regained weight at an average rate of 1.2% body weight per month for the first six months. Our approach with patients includes a 12-week taper: reduce from 2.4mg to 1.7mg for four weeks, then to 1.0mg for four weeks, then to 0.5mg for four weeks before stopping entirely. Pair this with increased protein intake (minimum 2.0g/kg), a structured resistance training program (3–4 sessions weekly), and metabolic monitoring (monthly weigh-ins and waist circumference measurements). Even with optimal transition protocols, expect some rebound. The goal is to limit regain to 20–30% of lost weight rather than the typical 66%.

What If I Experience Persistent Nausea Beyond the First Three Months?

Nausea that doesn't resolve by week 12–16 occurs in approximately 7–9% of patients and typically indicates one of three issues: (1) too-rapid dose escalation. If you moved from 1.7mg to 2.4mg in a single four-week step, consider reverting to 1.7mg for an additional month before re-attempting the increase; (2) high-fat meal consumption. GLP-1 agonists slow gastric emptying, so fatty meals sit in the stomach longer and provoke nausea. Shift to lower-fat, higher-protein meals; (3) injection timing relative to meals. Some patients tolerate injections better when administered in the evening after dinner rather than morning before eating. If nausea persists despite these adjustments, switching to tirzepatide may help. The dual GIP agonism appears to reduce nausea incidence compared to semaglutide monotherapy.

The Unflinching Truth About Long-Term GLP-1 Therapy

Here's the honest answer: wegovy 5 year results are excellent for weight retention and cardiovascular risk reduction, but they require continuous treatment. The medication doesn't cure obesity. It manages it. The moment you stop, your ghrelin levels rise, your satiety signaling diminishes, and your body reverts to the hormonal state that created the weight gain originally. This isn't a flaw in the medication; it's the reality of how GLP-1 receptor agonists work.

Some patients hear 'lifelong treatment' and feel discouraged. We see it differently. If a medication reduces your cardiovascular event risk by 20%, maintains a 10% body weight reduction at four years, and allows you to function without constant hunger and food preoccupation. That's not dependency, that's therapeutic success. You wouldn't expect a patient with hypertension to 'cure' their blood pressure and stop taking antihypertensives. Metabolic disease works the same way.

The disconnect comes from how weight loss medications were marketed historically. As temporary interventions to 'kickstart' weight loss before willpower and lifestyle changes took over. That model failed repeatedly because it misunderstood the biology. GLP-1 medications aren't scaffolding you remove once the structure is stable. They're the structure.

The longest wegovy 5 year results we'll have come from real-world cohorts, not controlled trials. Those patients. The ones who started in 2021 and are still on treatment in 2026. Are demonstrating what sustained therapy looks like outside trial conditions: manageable side effects, stable weight, reduced comorbidities, and the normalisation of weekly injections as routine medical management. That's the actual five-year outcome for patients who stay on therapy.

Our team works with patients who choose to stop for financial, personal, or medical reasons, and we support that decision. But we're transparent about the rebound data. If you're weighing whether to continue Wegovy long-term, the clinical evidence strongly favours continuation. Weight regain isn't failure on your part. It's the predictable consequence of removing the hormonal intervention. If that trade-off doesn't work for your situation, plan the transition carefully rather than hoping the weight loss will hold on its own. It won't.